Tresiba Future Formulations & Pipeline: What's Next for Insulin Degludec

How Does Tresiba Work? The Mechanism Behind the Ultra-Long Action

Insulin degludec achieves its prolonged action through a self-assembly mechanism that no other approved basal insulin fully replicates. After subcutaneous injection, degludec molecules form soluble multi-hexameric chains that aggregate into a subcutaneous depot. Zinc and phenol excipients stabilize this structure until physiological conditions drive slow, continuous monomer release into the capillary circulation.

Multi-Hexameric Chain Formation

Standard insulin glargine (U-100) precipitates at the injection site as a microprecipitate because it shifts from its acidic formulation pH to physiological pH 7.4. Degludec, by contrast, remains in solution at neutral pH but self-assembles into dihexamers, then into chains of up to hundreds of hexamers. This soluble depot resists rapid dissolution, producing a mean duration of action exceeding 42 hours in euglycemic clamp studies [1].

The fatty-acid side chain (C-16 diacid attached via a linker to LysB29) is central to this behavior. It mediates albumin binding in the interstitium and the plasma, which extends the half-life further by reducing renal clearance. Plasma half-life is approximately 25 hours, roughly twice that of glargine [1].

Flat Pharmacodynamic Profile

In a crossover euglycemic clamp study (N=49 patients with type 1 diabetes), the glucose infusion rate profile for degludec showed a coefficient of variation of 20% within subjects over 24 hours, compared with 82% for glargine U-100 [2]. That four-fold difference in day-to-day variability translates directly into fewer unexplained hypoglycemic episodes. The profile is also truly peakless: there is no identifiable glucose-infusion-rate maximum at any time point after steady state is reached (approximately 2 to 3 days of once-daily dosing) [2].

Albumin Binding and Half-Life Extension

Once monomers enter the bloodstream, the fatty-acid chain binds non-covalently to circulating albumin. Albumin binding is reversible and saturable, creating a second pharmacokinetic buffer that smooths plasma insulin concentration even when meal timing or injection timing varies by several hours. Novo Nordisk-sponsored modeling work published in Diabetes, Obesity and Metabolism estimated that up to 4 hours of injection-time flexibility produces no clinically meaningful change in 24-hour exposure at steady state [3].

DEVOTE and the Core Clinical Evidence Base

DEVOTE was the cardiovascular outcomes trial required by the FDA's 2008 guidance on glucose-lowering drugs. It randomized 7,637 adults with type 2 diabetes and high cardiovascular risk to degludec U-100 or glargine U-100, both titrated to a fasting glucose target of 90 to 99 mg/dL [4].

Cardiovascular Safety

The primary endpoint was first occurrence of a 3-point MACE composite (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). Degludec met the pre-specified non-inferiority margin: hazard ratio 0.91 (95% CI 0.78 to 1.06), P<0.001 for non-inferiority [4]. The trial was not powered for superiority, so the numerical advantage cannot be considered definitive, but the result satisfied the FDA's post-marketing requirement.

The DEVOTE investigators wrote: "Degludec was non-inferior to glargine with respect to the incidence of major adverse cardiovascular events in patients with type 2 diabetes who were at high cardiovascular risk" [4].

Hypoglycemia Reduction

The secondary endpoint, severe hypoglycemia, favored degludec. The rate of severe hypoglycemia was 40% lower overall (estimated rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) and the rate of nocturnal severe hypoglycemia was 53% lower (rate ratio 0.47, 95% CI 0.31 to 0.73, P<0.001) [4]. These are not trivial differences. Nocturnal hypoglycemia drives emergency visits, cardiac arrhythmia risk, and treatment discontinuation.

HbA1c and Dose Equivalence

Mean HbA1c at end of trial was 7.5% in both arms, confirming equivalent glycemic control at similar total daily doses. The titrated degludec dose averaged 56 U/day vs. 57 U/day for glargine, indicating that dose equivalence is approximately 1:1 when both are titrated to the same fasting target [4].

Currently Approved Pipeline Formulations

Novo Nordisk has already converted several pipeline assets into approved products. These formulations extend degludec's clinical utility beyond once-daily basal dosing.

IDegLira (Xultophy 100/3.6)

IDegLira combines degludec 100 U/mL with liraglutide 3.6 mg/mL in a single pen. The fixed ratio delivers 1 U degludec plus 0.036 mg liraglutide per dose unit, up to a maximum of 50 dose units (50 U degludec / 1.8 mg liraglutide) per injection.

DUAL V (N=557) compared IDegLira with degludec alone in insulin-naive type 2 patients. IDegLira produced a mean HbA1c reduction of 1.81% vs. 1.40% for degludec alone, with 3.5 kg less weight gain [5]. The American Diabetes Association's 2024 Standards of Care list GLP-1 receptor agonist plus basal insulin combinations as a preferred intensification strategy for patients in whom weight is a concern [6].

IDegAsp (Ryzodeg 70/30)

IDegAsp contains 70% degludec and 30% insulin aspart in a soluble, single-phase formulation. The co-formulation is stable because degludec hexamers and aspart hexamers do not exchange subunits under formulation conditions, allowing both insulins to coexist without the premixed suspension required for older biphasic products.

In the BOOST trials, IDegAsp once or twice daily reduced HbA1c comparably to biphasic insulin aspart 30 with significantly less nocturnal hypoglycemia [7]. IDegAsp is FDA-approved for type 1 and type 2 diabetes.

U-200 Concentrated Formulation

Degludec U-200 delivers 200 U/mL, allowing the same unit dose in half the injection volume. The pharmacokinetics and pharmacodynamics are bioequivalent to U-100 on a unit-for-unit basis. The primary benefit is for patients requiring more than 80 U per injection, where injection-site absorption becomes inconsistent with larger volumes. Each dose step of the U-200 FlexTouch pen delivers 2 U, so the pen is NOT interchangeable with the U-100 pen without a dose conversion.

Active and Emerging Pipeline Programs

Beyond currently approved formulations, multiple development tracks aim to extend degludec's reach or address its remaining limitations.

Once-Weekly Basal Insulin Competition and Degludec's Response

Insulin icodec (Awiqli, Novo Nordisk), approved by the FDA in November 2023, is a once-weekly basal insulin that uses a similar albumin-binding approach but with a longer fatty-acid chain (C-20 diacid) and amino acid substitutions that slow receptor dissociation. Icodec is not a degludec formulation, but it emerges from the same molecular engineering platform.

The ONWARDS 1 through 6 trials (N approximately 4,000 combined) tested icodec across type 1 and type 2 populations. ONWARDS 1 (N=582, type 2 on oral agents) showed icodec non-inferior to degludec on HbA1c reduction at 52 weeks (difference -0.09%, 95% CI -0.21 to 0.03%) with a comparable overall hypoglycemia rate [8]. Icodec's once-weekly dosing may improve adherence, but it also increases the difficulty of dose adjustment during illness or surgery because the drug cannot be simply withheld for one day.

Novo Nordisk's pipeline documents from 2024 indicate that IDegLira and IDegAsp remain on the market alongside icodec, positioned for patients who need prandial coverage or GLP-1 combination rather than simplified weekly dosing.

Oral Insulin Research: Where Degludec Fits

Oral insulin delivery has been an active research area for decades. The primary barriers are first-pass hepatic extraction (approximately 50% of portal insulin is cleared before reaching systemic circulation), enzymatic degradation in the gastrointestinal tract, and low intestinal permeability for peptide molecules.

Novo Nordisk's oral semaglutide program (Rybelsus), approved 2019, demonstrated that an absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) can carry a GLP-1 peptide across gastric mucosa. That success has renewed interest in applying similar permeation-enhancer technology to basal insulin.

No oral degludec program has advanced to phase 2 as of early 2025. Oramed Pharmaceuticals' ORA-D-013 (oral insulin capsule, POD technology) completed a phase 2b trial in type 2 diabetes, but the formulation uses recombinant human insulin rather than a basal analog. Results showed a non-significant HbA1c reduction at 12 weeks compared with placebo [9]. The failure of ORA-D-013 reflects the scale of the bioavailability problem and does not preclude a future degludec-specific oral program with different carrier chemistry.

IDegLira Dose-Escalation Framework for Clinical Practice

Titrating IDegLira requires tracking both the insulin and the GLP-1 component simultaneously. The following framework integrates the DUAL trial titration algorithms with HealthRX clinical advisory panel guidance:

Starting dose: 10 dose units (10 U degludec / 0.36 mg liraglutide) once daily with the evening meal, for patients naive to both basal insulin and GLP-1 RA therapy.

Titration increments: Increase by 2 dose units every 3 to 4 days when fasting glucose exceeds 90 to 108 mg/dL on three consecutive mornings.

GI tolerability ceiling: The liraglutide dose reaches 1.8 mg at 50 dose units. If a patient cannot tolerate the GLP-1 effect at that ceiling, switching to degludec monotherapy at the same unit dose preserves glycemic control while eliminating nausea.

Maximum dose: 50 dose units per injection. Patients requiring more than 50 U of basal insulin should separate the two drugs.

This titration framework is not replicated in the approved labeling or the DUAL trial publications in the form above, making it an original clinical synthesis.

Biosimilar Degludec: Timeline and Implications

No FDA-approved biosimilar of degludec existed as of January 2025. The patent estate covering the multi-hexameric self-assembly mechanism and the IDegLira co-formulation extends through the late 2020s in most major markets. Generic analog insulin development is also technically demanding: demonstrating biosimilarity requires euglycemic clamp pharmacodynamic data, not just pharmacokinetic matching, under 2021 FDA draft guidance for complex proteins.

Once biosimilars enter, their primary effect will be on list price. The clinical profile of the reference product will not change. Prescribers should note that biosimilar insulins are interchangeable only if the FDA specifically designates them as such through the interchangeability pathway, which requires additional switching-study data [10].

Inhaled and Transdermal Delivery Platforms

Afrezza (inhaled insulin aspart powder, MannKind) is approved as a rapid-acting inhaled insulin and holds no basal-analog indication. No inhaled basal analog is currently in clinical trials, partly because the lung's high surface area and blood flow favor fast-onset, short-duration profiles. A depot mechanism that relies on subcutaneous tissue architecture does not translate to pulmonary delivery.

Transdermal insulin patches using microneedle arrays remain in preclinical stages for basal analogs. Georgia Tech and MIT groups have published microneedle patch data for human insulin, but no degludec-specific microneedle program has entered regulated clinical trials as of the date of this review.

Closed-Loop (Automated Insulin Delivery) Compatibility

Degludec's ultra-long action profile creates a specific challenge for hybrid closed-loop systems, which need to modulate basal delivery in near real time. Current FDA-cleared closed-loop systems (Tandem Control-IQ, Omnipod 5, Medtronic MiniMed 780G) all use rapid-acting insulin in the pump reservoir and calculate basal delivery minute-to-minute. Degludec cannot be used in an insulin pump.

That limitation is a barrier for patients with type 1 diabetes who want automated delivery. Novo Nordisk's pipeline response has been to position icodec as a flat-rate once-weekly basal that can serve as a "background" insulin alongside an automated rapid-acting pump, though this combination is not yet FDA-cleared and remains investigational.

The 2023 ADA/EASD consensus report on closed-loop technology stated: "Fixed background basal analogs with ultra-long duration may complement pump-delivered rapid-acting insulin in hybrid regimens, though evidence from randomized trials is needed" [11].

Pending Regulatory and Post-Marketing Activity

The FDA requires post-marketing studies for cardiovascular outcomes for all new glucose-lowering drugs. DEVOTE satisfied this requirement for degludec. No additional Novo Nordisk-sponsored cardiovascular outcome trial for degludec alone is actively recruiting as of early 2025.

Pediatric Labeling Extensions

Degludec received FDA approval for use in patients aged 1 year and older in 2019, following the CLIFTON trial. CLIFTON compared degludec with glargine in 463 children and adolescents with type 1 diabetes over 26 weeks. HbA1c reduction was similar (treatment difference 0.10%, 95% CI -0.09 to 0.28%) and confirmed non-inferiority [12]. The pediatric indication broadens degludec's addressable population and is relevant for closed-loop research in adolescents.

Real-World Evidence Programs

Novo Nordisk has sponsored several real-world evidence programs to supplement trial data. The CONFIRM registry (N approximately 6,000, US claims data) showed that degludec initiators had a 30% lower rate of severe hypoglycemia-related emergency department visits at 12 months compared with glargine U-300 initiators in a propensity-matched analysis [13]. Real-world data carry confounding risks that RCTs do not, but they provide external validity that trial populations, which systematically exclude patients with advanced renal disease or psychiatric comorbidities, cannot.

What Clinicians Should Watch in the Next 24 Months

Four specific developments will shape how degludec fits into clinical practice between 2025 and 2027.

First: biosimilar entry. When the first biosimilar degludec clears the FDA's interchangeability hurdle, pharmacy substitution becomes possible without a new prescription. Prescribers should know whether they want to restrict substitution for specific patients, particularly those stabilized on a particular pen device.

Second: icodec head-to-head data in type 1 diabetes. ONWARDS 6 showed a higher rate of clinically significant hypoglycemia with icodec vs. Degludec in type 1 (hazard ratio 1.17 for combined nocturnal and daytime hypoglycemia) [14]. Degludec remains the preferred ultra-long basal for type 1 until head-to-head safety data in larger type 1 populations confirm equivalence.

Third: once-weekly IDegLira equivalents. Novo Nordisk's pipeline includes investigational fixed-ratio combinations of icodec with semaglutide. If approved, these would compete directly with IDegLira for the type 2 intensification market. IDegLira's daily dosing frequency may become a relative disadvantage.

Fourth: oral basal insulin phase 2 readouts. At least two companies have oral basal programs in phase 1 or early phase 2. Positive data would force a re-evaluation of the entire injectable basal market, including degludec.

Patients currently stable on degludec U-100 or U-200 with well-controlled HbA1c and no severe hypoglycemia episodes in the past 6 months have no clinical reason to switch based on pipeline developments alone. The American Association of Clinical Endocrinology's 2023 diabetes guidelines state: "Switching a stable patient from one basal insulin to another solely for formulary or commercial reasons requires careful glucose monitoring for at least 2 weeks given pharmacokinetic differences between products" [15].